Global Alpha Capital Management Ltd. Buys 1,337 Shares of Vericel Co. (NASDAQ:VCEL)

Global Alpha Capital Management Ltd. boosted its position in Vericel Co. (NASDAQ:VCEL) by 5.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 24,720 shares of the biotechnology company’s stock after acquiring an additional 1,337 shares during the quarter. Global Alpha Capital Management Ltd.’s holdings in Vericel were worth $1,357,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Creative Planning purchased a new position in shares of Vericel in the 3rd quarter worth about $230,000. International Assets Investment Management LLC lifted its position in Vericel by 4,126.7% in the 3rd quarter. International Assets Investment Management LLC now owns 634 shares of the biotechnology company’s stock worth $27,000 after buying an additional 619 shares during the last quarter. Farther Finance Advisors LLC boosted its stake in Vericel by 48.1% in the third quarter. Farther Finance Advisors LLC now owns 1,247 shares of the biotechnology company’s stock worth $53,000 after buying an additional 405 shares in the last quarter. Summit Global Investments grew its position in Vericel by 105.4% during the third quarter. Summit Global Investments now owns 20,831 shares of the biotechnology company’s stock valued at $880,000 after acquiring an additional 10,691 shares during the last quarter. Finally, Atria Investments Inc raised its stake in shares of Vericel by 21.6% during the third quarter. Atria Investments Inc now owns 7,768 shares of the biotechnology company’s stock worth $328,000 after acquiring an additional 1,378 shares in the last quarter.

Insider Buying and Selling at Vericel

In other Vericel news, insider Jonathan Siegal sold 1,092 shares of the business’s stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $61.99, for a total transaction of $67,693.08. Following the transaction, the insider now directly owns 1,206 shares of the company’s stock, valued at approximately $74,759.94. The trade was a 47.52 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Robert L. Md Zerbe sold 2,500 shares of the firm’s stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $62.50, for a total transaction of $156,250.00. Following the completion of the sale, the director now directly owns 26,595 shares of the company’s stock, valued at approximately $1,662,187.50. This represents a 8.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 7,500 shares of company stock valued at $466,200 in the last 90 days. Insiders own 5.20% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on VCEL. Stephens reaffirmed an “overweight” rating and issued a $65.00 price objective on shares of Vericel in a research note on Wednesday, January 15th. Canaccord Genuity Group upped their price target on shares of Vericel from $64.00 to $67.00 and gave the company a “buy” rating in a research report on Monday, February 3rd. BTIG Research lifted their price objective on Vericel from $56.00 to $66.00 and gave the stock a “buy” rating in a report on Tuesday, November 26th. Truist Financial restated a “buy” rating and set a $61.00 target price (down from $67.00) on shares of Vericel in a report on Monday, March 3rd. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $60.00 price target on shares of Vericel in a research note on Friday, February 28th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $62.29.

Vericel Trading Up 1.6 %

Vericel stock opened at $49.56 on Friday. The firm has a market cap of $2.48 billion, a P/E ratio of 826.14 and a beta of 1.78. Vericel Co. has a 1-year low of $39.12 and a 1-year high of $63.00. The firm has a 50-day moving average of $56.48 and a 200-day moving average of $51.92.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.